IMPAACT 2047 / Radiant-Moms Plus

IMPAACT 2047/ Radiant-Moms Plus (Rifapentine in High Doses in Pregnancy with TB) is a Phase II, two-arm, multi-site, randomized study evaluating the safety, tolerability, and pharmacokinetics of high-dose rifapentine combined with moxifloxacin in pregnant people with tuberculosis. Pregnant people living with and without HIV will be enrolled. The study is designed to compare a four-month daily tuberculosis treatment regimen 4HPMZ [isoniazid (H), high-dose rifapentine (P), moxifloxacin (M) and pyrazinamide (Z)] with a six-month daily tuberculosis treatment regimen 6HRZE [isoniazid (H), rifampin (R), pyrazinamide (Z), and ethambutol (E)]. Participants will be followed for 12 months post-treatment initiation. Site selection for this study has not yet occurred.